The user reports hair growth improvements after using topical minoxidil, oral finasteride, and weekly dermarolling for about three months, but is experiencing dandruff, possibly due to the minoxidil.
A user shared a 4-month update showing thicker and healthier hair after using finasteride and minoxidil. Advice was given on how to better track progress, especially with curly hair.
The user reports significant hair regrowth after 10 months using 1 mg oral finasteride daily and a 1.25 mm derma stamp bi-weekly with rosemary and jojoba oil. Other users commend the progress and inquire about the routine and side effects.
A 35-year-old male has been using finasteride inconsistently for two years and is hesitant about using minoxidil due to potential side effects. He is considering oral minoxidil and microneedling as alternatives and is unsure if dutasteride is too strong.
A user's progress with treating hair loss, using minoxidil, finasteride and microneedling. The user experienced impressive results after four months of treatment, and mentioned that stopping recreational drugs and losing weight helped their hair regrowth.
The user is allergic to minoxidil and experienced severe itching and redness. They are considering alternatives like finasteride, dutasteride, and dermarolling for hair loss treatment.
A user shared their 20-week progress using topical minoxidil (5%) and finasteride (0.1%) with a 1mm dermastamp, showing significant hair regrowth from NW5 to between NW3V and NW4. They experienced no side effects and plan to update at 12 months.
The conversation is about the effectiveness and side effects of 5% Nanoxidil for hair loss, with concerns about shedding and whether once-daily application is sufficient. The user is comparing it to 5% Minoxidil.
RU58841 should be applied directly to the scalp, ideally once a day, a few hours before bed. Some users experienced side effects like shedding and systemic issues when using RU58841 and Minoxidil together, while others reported no side effects when using RU58841 alone.
Microneedling can still be beneficial when using oral finasteride and minoxidil, with a recommended needle length of 0.5mm to 1.0mm. A stamp or pen is preferred over a roller for microneedling.
The user is taking dutasteride 0.5mg daily and seeks a topical androgen inhibitor for the scalp. They are looking for recommendations to enhance their hair loss treatment.
The conversation discusses a user's three-month progress using topical finasteride once a day, 6% minoxidil at night, and weekly dermastamping at 1.25mm for hair loss. Commenters note the impressive results and discuss application methods and safety precautions for family members.
A 20-year-old is using a topical solution with 0.1% finasteride and 7% minoxidil for hair loss, applying about 10 drops daily. They seek advice on the correct dosage to avoid over or under-application.
The user is experiencing increased hair miniaturization despite using oral minoxidil, dutasteride, and microneedling. They are considering reintroducing finasteride and adjusting dutasteride dosage.
A 19-year-old trans female has been using topical minoxidil and dermarolling for nearly two months, alongside oral minoxidil, finasteride, spironolactone, and estrogen. She noticed significant hair improvement after starting topical minoxidil and dermarolling.
The user cannot handle Minoxidil and is looking for an alternative to dilute topical finasteride. They are considering using Alpecin liquid as a solution.
A 25-year-old male shared progress pictures after 50 days of treating hair loss with minoxidil and dermarolling. He previously tried finasteride but stopped due to side effects.
Creating custom topical treatments for hair loss using minoxidil, finasteride, and RU58841. It includes recipes and instructions for home preparation, focusing on cost savings and customization.
The conversation is about hair regrowth progress using a combination of treatments: dutasteride, minoxidil, RU58841, ketoconazole, and monthly microneedling. The user reports that microneedling and topical minoxidil had the most impact on their hairline.
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.
The user is starting microneedling for hair loss and is concerned about cleaning the needles and post-treatment care, including sun exposure and applying products like rosemary oil. They use a microneedling pen and are seeking advice on timing and technique.
The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.
The user experienced significant hair regrowth over 8 months using a topical combination of 0.3% finasteride and 6% minoxidil, applied nightly, along with weekly microneedling and ketoconazole shampoo. They reported no side effects and attributed the improvement mainly to minoxidil, while maintaining consistent use of supplements and a healthy lifestyle.
The post discusses an 11-month hair loss treatment journey using dutasteride, minoxidil, nizoral, and 1.5mm derma rolling. The responses inquire about the frequency of derma rolling and express optimism for further progress.
The conversation is about a topical spray containing finasteride, minoxidil, and tretinoin, with users discussing its effectiveness compared to more established brands. One user mentions using a product with 5% minoxidil, 0.15% finasteride, and 0.15% tretinoin.
The conversation discusses using a mixture of 4% peppermint oil in jojoba oil to reduce flaking and dandruff caused by 5% Minoxidil lotion. The user reports significant improvement after one application of the oil mixture.
Treating hair loss with finasteride, minoxidil, keto diet, and microneedling; the user has seen good results but wants to focus more on their temples; another user suggested using an exfoliating comb while shampooing.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.